1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Colectomy incidence rates in five-year data from the observational postmarketing ulcerative colitis study of originator infliximab
(
- Contribution to journal › Article
- 2019
-
Mark
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
(
- Contribution to journal › Article
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2012
-
Mark
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: A retrospective observational study
(
- Contribution to journal › Article
-
Mark
High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis
(
- Contribution to journal › Scientific review
- 2007
-
Mark
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials
(
- Contribution to journal › Article